Cardiovascular safety of biologic therapies for the treatment of RA.
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentThe Role of Efferocytosis in Atherosclerosis.T cell immunity and cardiovascular metabolic disorders: does metabolism fuel inflammation?CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.Exploring the Crosstalk between Adipose Tissue and the Cardiovascular System.Advances in psoriasis treatment: experts comment on recent developments.Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis.Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.Methotraxate-Loaded Hybrid Nanoconstructs Target Vascular Lesions and Inhibit Atherosclerosis Progression in ApoE-/- Mice.
P2860
Q28074148-10C8B624-0377-432F-9934-D9A1E46559CFQ30240180-1E2FBBE3-51D5-4258-99F5-B07558296FE1Q34563216-06C6E7E1-AEE2-4C4E-97A2-57C69B701D9FQ34680660-44DA5046-DE3C-4852-9659-13BFB147BE56Q36057159-CA91748B-611A-4465-A33E-2F4014EF5146Q37165792-1BCBDAD0-22D9-43B2-ACE9-094A186337ECQ38673326-862F0C96-2C33-4192-915B-F15D3E3590CEQ40959053-A993B7DD-C9DA-47A9-8C63-B3B614EADD08Q41686212-3291DF28-809E-4CB3-A93B-13FBFC7EA62EQ41833324-4E9B47C8-DF8B-4B75-9AFA-0BDDDCF5DEF7Q41919670-CCEFA412-7410-46E8-B6D7-C5A6F1D7B619Q42701584-E8A45B0B-FF40-41A6-B624-A4BE4425CB1DQ49788530-E3AEB33F-BE38-455A-B78D-8DE700AF7229Q50659065-CCF1CC57-DA9E-448D-8C79-47EB753C46F6
P2860
Cardiovascular safety of biologic therapies for the treatment of RA.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Cardiovascular safety of biologic therapies for the treatment of RA.
@en
Cardiovascular safety of biologic therapies for the treatment of RA.
@nl
type
label
Cardiovascular safety of biologic therapies for the treatment of RA.
@en
Cardiovascular safety of biologic therapies for the treatment of RA.
@nl
prefLabel
Cardiovascular safety of biologic therapies for the treatment of RA.
@en
Cardiovascular safety of biologic therapies for the treatment of RA.
@nl
P2093
P2860
P356
P1476
Cardiovascular safety of biologic therapies for the treatment of RA.
@en
P2093
Jeffrey D Greenberg
Michael E Farkouh
Victoria Furer
P2860
P2888
P356
10.1038/NRRHEUM.2011.168
P407
P577
2011-11-15T00:00:00Z